Anti-TNF biosimilars in inflammatory bowel disease: searching the proper patient's profile?

Research output: Contribution to journalArticle

Abstract

Biosimilars of infliximab (CT-P13) are currently approved and available for the same indications as the originator. Some concerns about safety and immunogenicity have risen in the past because of lack of data in IBD. Since 2015, several cohort studies have been conducted in IBD showing that CT-P13 has comparable safety and efficacy profile to the originator, both in adult and pediatric population, either in naïve patients, or even in those who switched from the originator to CT-P13. This review aims to analyze the current literature data in order to define a clear patient profile, to identify those IBD patients who would benefit the most from the use of CT-P13.

Original languageEnglish
JournalCurrent Medicinal Chemistry
DOIs
Publication statusE-pub ahead of print - May 13 2018

Fingerprint

Biosimilar Pharmaceuticals
Inflammatory Bowel Diseases
Safety
Pediatrics
Cohort Studies
CT-P13
Population

Cite this

@article{7ae98d20f208438894b3bd0fb7e60d42,
title = "Anti-TNF biosimilars in inflammatory bowel disease: searching the proper patient's profile?",
abstract = "Biosimilars of infliximab (CT-P13) are currently approved and available for the same indications as the originator. Some concerns about safety and immunogenicity have risen in the past because of lack of data in IBD. Since 2015, several cohort studies have been conducted in IBD showing that CT-P13 has comparable safety and efficacy profile to the originator, both in adult and pediatric population, either in na{\"i}ve patients, or even in those who switched from the originator to CT-P13. This review aims to analyze the current literature data in order to define a clear patient profile, to identify those IBD patients who would benefit the most from the use of CT-P13.",
author = "Silvio Danese and Gionata Fiorino",
note = "Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
year = "2018",
month = "5",
day = "13",
doi = "10.2174/0929867325666180514100204",
language = "English",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Anti-TNF biosimilars in inflammatory bowel disease

T2 - searching the proper patient's profile?

AU - Danese, Silvio

AU - Fiorino, Gionata

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

PY - 2018/5/13

Y1 - 2018/5/13

N2 - Biosimilars of infliximab (CT-P13) are currently approved and available for the same indications as the originator. Some concerns about safety and immunogenicity have risen in the past because of lack of data in IBD. Since 2015, several cohort studies have been conducted in IBD showing that CT-P13 has comparable safety and efficacy profile to the originator, both in adult and pediatric population, either in naïve patients, or even in those who switched from the originator to CT-P13. This review aims to analyze the current literature data in order to define a clear patient profile, to identify those IBD patients who would benefit the most from the use of CT-P13.

AB - Biosimilars of infliximab (CT-P13) are currently approved and available for the same indications as the originator. Some concerns about safety and immunogenicity have risen in the past because of lack of data in IBD. Since 2015, several cohort studies have been conducted in IBD showing that CT-P13 has comparable safety and efficacy profile to the originator, both in adult and pediatric population, either in naïve patients, or even in those who switched from the originator to CT-P13. This review aims to analyze the current literature data in order to define a clear patient profile, to identify those IBD patients who would benefit the most from the use of CT-P13.

U2 - 10.2174/0929867325666180514100204

DO - 10.2174/0929867325666180514100204

M3 - Article

C2 - 29756565

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

ER -